REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
For Alzheimer's Agitation, Promising News from Rexulti
Leqembi Granted Full FDA Approval to Treat Early Alzheimer's Disease
agitation that may happen with dementia due to Alzheimer's disease
Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval
FDA Approves First Treatment for Alzheimer's Agitation
Antipsychotic Drug Reduces Alzheimer's-Associated Agitation
Rexulti On Track To Add Claim For Alzheimer's Dementia Agitation
Lundbeck, Otsuka drug cut agitation in Alzheimer's patients
A first: FDA approves drug to treat agitation in Alzheimer's
Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti
Important News for Older Adults: FDA Approves First Drug to Treat
de
por adulto (o preço varia de acordo com o tamanho do grupo)
